



(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 1/16 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2021/039974

(22) International Filing Date:

30 June 2021 (30.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/047,221	01 July 2020 (01.07.2020)	US
63/090,158	09 October 2020 (09.10.2020)	US
63/151,561	19 February 2021 (19.02.2021)	US
63/213,155	21 June 2021 (21.06.2021)	US

(71) Applicant: **SILVERBACK THERAPEUTICS, INC.**
[US/US]; 500 Fairview Ave N, Suite 600, Seattle, Wash-
ington 98109 (US).

(72) Inventors: **BAUM, Peter R.**; c/o Silverback Therapeutics,
Inc., 500 Fairview Ave N, Suite 600, Seattle, Washington

98109 (US). **DUBOSE, Robert**; c/o Silverback Therapeu-
tics, Inc., 500 Fairview Ave N, Suite 600, Seattle, Wash-
ington 98109 (US). **ODEGARD, Valerie**; c/o Silverback
Therapeutics, Inc., 500 Fairview Ave N, Suite 600, Seat-
tle, Washington 98109 (US). **TAN, Philip**; c/o Silverback
Therapeutics, Inc., 500 Fairview Ave N, Suite 600, Seat-
tle, Washington 98109 (US). **THOMPSON, Peter A.**; c/o
Silverback Therapeutics, Inc., 500 Fairview Ave N, Suite
600, Seattle, Washington 98109 (US). **SMITH, Sean W.**; c/
o Silverback Therapeutics, Inc., 500 Fairview Ave N, Suite
600, Seattle, Washington 98109 (US). **STEVENS, Bren-
da**; c/o Silverback Therapeutics, Inc., 500 Fairview Ave N,
Suite 600, Seattle, Washington 98109 (US).

(74) Agent: **SUN, Eileen, S.** et al.; Seed Intellectual Property
Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle,
Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

(54) Title: ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF




FIG. 1A

(57) Abstract: The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.

[Continued on next page]

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))